Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210389347> ?p ?o ?g. }
- W4210389347 endingPage "343" @default.
- W4210389347 startingPage "336" @default.
- W4210389347 abstract "Anticoagulant and antiplatelet therapy have become increasingly popular. The goal of therapy is to prevent venous thromboembolism and platelet aggregation, respectively. Traditional anticoagulant and antiplatelet drugs are quickly being replaced with novel medications with more predictable pharmacokinetics. Unfortunately, these drugs carry the risk of uncontrolled hemorrhage because of drug-induced coagulopathy. Uncontrolled hemorrhage continues to be a major cause of preventable death: hemorrhage accounts for approximately 30% of trauma-related deaths, second to brain injury. Controlling hemorrhage while dealing with comorbidities remains a challenge to clinicians. There are many gaps in care and knowledge that contribute to the struggle of treating this patient population.This literature review is focused on the most effective ways to achieve hemostasis in a patient with drug-induced coagulopathy. The antiplatelet therapies aspirin, clopidogrel, ticlopidine, pasugrel, and ticagrelor are analyzed. Anticoagulant therapies are also reviewed, including warfarin, rivaroxaban, apixaban, edoxaban, and dabigatran. In addition, viscoelastic testing and platelet function assays are reviewed for their ability to monitor drug effectiveness and to accurately depict the patient's ability to clot. This review focuses on articles from the past 10 years. However, there are limitations to the 10-year restriction, including no new research posted within the 10-year timeline on particular subjects. The most recent article was then used where current literature did not exist (within 10 years).Traditional anticoagulants have unpredictable pharmacokinetics and can be difficult to correct in bleeding emergencies. Vitamin K has been proven to reliably and effectively reverse the effect of vitamin K antagonists (VKAs) while having a lower anaphylactoid risk than frozen plasma. Prothrombin complex concentrates should be used when there is risk of loss of life or limb. Frozen plasma is not recommended as a first-line treatment for the reversal of VKAs. Novel anticoagulants have specific reversal agents such as idarucizumab for dabigatran and andexxa alfa for factor Xa (FXa) inhibitors. Although reliable, these drugs carry a large price tag. As with traditional anticoagulants, cheaper alternative therapies are available such as prothrombin complex concentrates. Finally, static coagulation testing works well for routine therapeutic drug monitoring but may not be appropriate during bleeding emergencies. Viscoelastic testing such as thromboelastography and rotational thromboelastometry depict in vivo hemostatic properties more accurately than static coagulation assays. Adding viscoelastic testing into resuscitation protocols may guide blood product usage more efficiently.This review is intended to be used as a guide. The topics covered in this review should be used as a reference for treating the conditions described. This review article also covers laboratory testing and is meant as a guide for physicians on best practices. These findings illustrate recommended testing and reversal techniques based off evidence-based medicine and literature." @default.
- W4210389347 created "2022-02-08" @default.
- W4210389347 creator A5067495539 @default.
- W4210389347 date "2022-01-24" @default.
- W4210389347 modified "2023-10-17" @default.
- W4210389347 title "Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review" @default.
- W4210389347 cites W1482291463 @default.
- W4210389347 cites W1530892454 @default.
- W4210389347 cites W1856335394 @default.
- W4210389347 cites W1877581810 @default.
- W4210389347 cites W1943551755 @default.
- W4210389347 cites W2001169909 @default.
- W4210389347 cites W2001208199 @default.
- W4210389347 cites W2011861566 @default.
- W4210389347 cites W2045627138 @default.
- W4210389347 cites W2075352627 @default.
- W4210389347 cites W2086011931 @default.
- W4210389347 cites W2090462746 @default.
- W4210389347 cites W2094800902 @default.
- W4210389347 cites W2101502513 @default.
- W4210389347 cites W2132647449 @default.
- W4210389347 cites W2149537406 @default.
- W4210389347 cites W2168492365 @default.
- W4210389347 cites W2171360908 @default.
- W4210389347 cites W2193505501 @default.
- W4210389347 cites W2222084438 @default.
- W4210389347 cites W2323559086 @default.
- W4210389347 cites W2338008241 @default.
- W4210389347 cites W2345433392 @default.
- W4210389347 cites W2359884680 @default.
- W4210389347 cites W2512686635 @default.
- W4210389347 cites W2534793136 @default.
- W4210389347 cites W2558194803 @default.
- W4210389347 cites W2598370951 @default.
- W4210389347 cites W2727872797 @default.
- W4210389347 cites W2728492498 @default.
- W4210389347 cites W2749348258 @default.
- W4210389347 cites W2762487553 @default.
- W4210389347 cites W2791662285 @default.
- W4210389347 cites W2901225791 @default.
- W4210389347 cites W2978423187 @default.
- W4210389347 cites W3042321076 @default.
- W4210389347 cites W4237953286 @default.
- W4210389347 doi "https://doi.org/10.1093/labmed/lmab115" @default.
- W4210389347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35073576" @default.
- W4210389347 hasPublicationYear "2022" @default.
- W4210389347 type Work @default.
- W4210389347 citedByCount "1" @default.
- W4210389347 countsByYear W42103893472022 @default.
- W4210389347 crossrefType "journal-article" @default.
- W4210389347 hasAuthorship W4210389347A5067495539 @default.
- W4210389347 hasConcept C126322002 @default.
- W4210389347 hasConcept C141071460 @default.
- W4210389347 hasConcept C177713679 @default.
- W4210389347 hasConcept C2776301958 @default.
- W4210389347 hasConcept C2777265216 @default.
- W4210389347 hasConcept C2777628954 @default.
- W4210389347 hasConcept C2777849778 @default.
- W4210389347 hasConcept C2778205648 @default.
- W4210389347 hasConcept C2778661090 @default.
- W4210389347 hasConcept C2778810321 @default.
- W4210389347 hasConcept C2779161974 @default.
- W4210389347 hasConcept C2779936836 @default.
- W4210389347 hasConcept C2780290652 @default.
- W4210389347 hasConcept C2780638905 @default.
- W4210389347 hasConcept C2908647359 @default.
- W4210389347 hasConcept C2911117829 @default.
- W4210389347 hasConcept C71924100 @default.
- W4210389347 hasConcept C99454951 @default.
- W4210389347 hasConceptScore W4210389347C126322002 @default.
- W4210389347 hasConceptScore W4210389347C141071460 @default.
- W4210389347 hasConceptScore W4210389347C177713679 @default.
- W4210389347 hasConceptScore W4210389347C2776301958 @default.
- W4210389347 hasConceptScore W4210389347C2777265216 @default.
- W4210389347 hasConceptScore W4210389347C2777628954 @default.
- W4210389347 hasConceptScore W4210389347C2777849778 @default.
- W4210389347 hasConceptScore W4210389347C2778205648 @default.
- W4210389347 hasConceptScore W4210389347C2778661090 @default.
- W4210389347 hasConceptScore W4210389347C2778810321 @default.
- W4210389347 hasConceptScore W4210389347C2779161974 @default.
- W4210389347 hasConceptScore W4210389347C2779936836 @default.
- W4210389347 hasConceptScore W4210389347C2780290652 @default.
- W4210389347 hasConceptScore W4210389347C2780638905 @default.
- W4210389347 hasConceptScore W4210389347C2908647359 @default.
- W4210389347 hasConceptScore W4210389347C2911117829 @default.
- W4210389347 hasConceptScore W4210389347C71924100 @default.
- W4210389347 hasConceptScore W4210389347C99454951 @default.
- W4210389347 hasIssue "4" @default.
- W4210389347 hasLocation W42103893471 @default.
- W4210389347 hasLocation W42103893472 @default.
- W4210389347 hasOpenAccess W4210389347 @default.
- W4210389347 hasPrimaryLocation W42103893471 @default.
- W4210389347 hasRelatedWork W2018877821 @default.
- W4210389347 hasRelatedWork W2083901189 @default.
- W4210389347 hasRelatedWork W2093259736 @default.
- W4210389347 hasRelatedWork W2126328654 @default.
- W4210389347 hasRelatedWork W2134062404 @default.
- W4210389347 hasRelatedWork W2167924766 @default.